Literature DB >> 3967425

Pathologic fracture risk in rehabilitation of patients with bony metastases.

R Bunting, W Lamont-Havers, D Schweon, A Kliman.   

Abstract

Fifty-four patients with metastatic bone disease were followed prospectively to assess the risk of pathologic fracture during rehabilitation. Sixteen fractures were observed in 12 patients. Only one fracture occurred while the patient was undergoing rehabilitation, and this was a fourth lumbar vertebral compression that did not affect the clinical course of the patient. Patients in the fracture group were generally younger, female, and in a more advanced stage of disease with lytic metastases and a previous occurrence of pathologic fracture.

Entities:  

Mesh:

Year:  1985        PMID: 3967425

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  12 in total

1.  Non-invasive assessment of failure torque in rat bones with simulated lytic lesions using computed tomography based structural rigidity analysis.

Authors:  Vahid Entezari; Pamela A Basto; Vartan Vartanians; David Zurakowski; Brian D Snyder; Ara Nazarian
Journal:  J Biomech       Date:  2011-02-03       Impact factor: 2.712

2.  Treatment Planning and Fracture Prediction in Patients with Skeletal Metastasis with CT-Based Rigidity Analysis.

Authors:  Ara Nazarian; Vahid Entezari; David Zurakowski; Nathan Calderon; John A Hipp; Juan C Villa-Camacho; Patrick P Lin; Felix H Cheung; Albert J Aboulafia; Robert Turcotte; Megan E Anderson; Mark C Gebhardt; Edward Y Cheng; Richard M Terek; Michael Yaszemski; Timothy A Damron; Brian D Snyder
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

3.  In brief: classifications in brief: Mirels' classification: metastatic disease in long bones and impending pathologic fracture.

Authors:  Muhammad Umar Jawad; Sean P Scully
Journal:  Clin Orthop Relat Res       Date:  2010-10       Impact factor: 4.176

4.  Computed tomography-based structural analysis for predicting fracture risk in children with benign skeletal neoplasms: comparison of specificity with that of plain radiographs.

Authors:  Natalie L Leong; Megan E Anderson; Mark C Gebhardt; Brian D Snyder
Journal:  J Bone Joint Surg Am       Date:  2010-08-04       Impact factor: 5.284

Review 5.  A Focused Review of Safety Considerations in Cancer Rehabilitation.

Authors:  Susan Maltser; Adrian Cristian; Julie K Silver; G Stephen Morris; Nicole L Stout
Journal:  PM R       Date:  2017-09       Impact factor: 2.298

6.  CT-based Structural Rigidity Analysis Is More Accurate Than Mirels Scoring for Fracture Prediction in Metastatic Femoral Lesions.

Authors:  Timothy A Damron; Ara Nazarian; Vahid Entezari; Carlos Brown; William Grant; Nathan Calderon; David Zurakowski; Richard M Terek; Megan E Anderson; Edward Y Cheng; Albert J Aboulafia; Mark C Gebhardt; Brian D Snyder
Journal:  Clin Orthop Relat Res       Date:  2016-03       Impact factor: 4.176

Review 7.  The effects of metastatic lesion on the structural determinants of bone: Current clinical and experimental approaches.

Authors:  Stacyann Bailey; David Hackney; Deepak Vashishth; Ron N Alkalay
Journal:  Bone       Date:  2019-11-21       Impact factor: 4.398

8.  Effect of the metastatic defect on the structural response and failure process of human vertebrae: an experimental study.

Authors:  Ron N Alkalay
Journal:  Clin Biomech (Bristol, Avon)       Date:  2014-10-12       Impact factor: 2.034

9.  Strategy for bone metastases treatment in patients with impending cord compression or vertebral fractures: a pilot study.

Authors:  N Rasulova; V Lyubshin; F Djalalov; K H Kim; L Nazirova; N Ormanov; D Arybzhanov
Journal:  World J Nucl Med       Date:  2011-01

10.  Augmentation of failed human vertebrae with critical un-contained lytic defect restores their structural competence under functional loading: An experimental study.

Authors:  Ron N Alkalay; Dietrich von Stechow; David B Hackney
Journal:  Clin Biomech (Bristol, Avon)       Date:  2015-03-28       Impact factor: 2.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.